Targeted treatments for breast cancer: a step forward
Mené dans 204 centres hospitaliers de 25 pays sur 808 patientes atteintes d'un cancer métastatique du sein HER2+ (durée médiane de suivi : 30 mois), cet essai de phase III évalue, du point de vue de la survie sans progression, l'ajout de pertuzumab à un traitement de première ligne combinant trastuzumab et docétaxel
Breast cancer was the first solid tumour for which targeted treatments were available. Endocrine therapy—targeting the oestrogen receptor—was described more than 100 years ago and, as biological knowledge has grown, major advances in treatment and prevention of breast cancer have been made. Classification of molecular subtypes of breast cancer highlighted the importance of the oestrogen receptor and the HER2 oncogenic pathway in some populations. Furthermore, discovery of the role of HER2 sign ...
The Lancet Oncology , commentaire, 2012